Thesis
ACR-368 pursues accelerated approval in serous endometrial cancer on 52% cORR; the bet is whether FDA accepts Phase 2b as registrational without a Phase 3 requirement first
ACR-368, a CHK1/2 inhibitor, is in a registrational-intent Phase 2b trial targeting platinum- and anti-PD-1-failed serous endometrial cancer patients with up to two prior lines of therapy. The thesis resolves if FDA accepts the Phase 2b data package—anchored by a 52% cORR in serous EC—as the basis for accelerated approval without mandating Phase 3 completion first. The primary risk is regulatory: FDA may require the Phase 3 confirmatory trial to mature before granting any approval, and lifileucel from Iovance addresses an overlapping post-platinum/post-checkpoint endometrial population with a competing modality.
Focus
ACR-368-201 Arm 3 enrollment completion
H2 2026
Bull
Arm 3 enrolls on schedule across US and EU sites, generating a well-powered prospective dataset confirming the 52% cORR in all-comer serous EC patients with two prior lines of therapy including chemotherapy and anti-PD-1. A completed, adequately sized cohort strengthens the regulatory argument that Phase 2b data is sufficient for accelerated approval without a prior Phase 3 requirement, enabling an NDA/BLA submission and validating the biomarker-independent (biopsy-independent) serous EC strategy.
Bear
Enrollment is slower than projected across US and EU sites, delaying the dataset and compressing the runway to the Q3 2027 cash horizon, leaving insufficient time to complete the filing before a potential capital raise at an unfavorable position. Alternatively, even upon completion, FDA may deem the single-arm Phase 2b dataset insufficiently powered or require a randomized Phase 3 as a precondition for accelerated approval, rendering the enrollment milestone insufficient to de-risk the core thesis.
Unlock the full thesis for ACRV.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialRelated companies
Generated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.